AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37280696 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic oxygenated perfusion (HOPE) following classical static cold storage (4 °C) for 1 to 4 hours
Number of subjects: 0
Study 37280696 — intervention group
Group type: COMPARATOR
Intervention: Static cold storage (control group)
Number of subjects: 0
Study 37282500 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran
Number of subjects: 0
Study 37282500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37282666 — intervention group
Group type: EXPERIMENTAL
Intervention: Pralsetinib 400-mg once-daily oral
Number of subjects: 68
Study 37282797 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (conventional speech therapy and singing intervention)
Number of subjects: 33
Study 37282797 — intervention group
Group type: COMPARATOR
Intervention: Conventional speech therapy
Number of subjects: 33
Study 37282797 — intervention group
Group type: COMPARATOR
Intervention: Singing intervention
Number of subjects: 33
Study 37283558 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaning policy/protocol
Number of subjects: 1506
Study 37283558 — intervention group
Group type: EXPERIMENTAL
Intervention: IWS policy/protocol
Number of subjects: 1506
Study 37283558 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaning policy/protocol utilization
Number of subjects: 1506
Study 37283558 — intervention group
Group type: EXPERIMENTAL
Intervention: IWS policy/protocol utilization
Number of subjects: 1506
Study 37283558 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaning policy/protocol based on duration of opioid/sedative use
Number of subjects: 1506
Study 37283558 — intervention group
Group type: EXPERIMENTAL
Intervention: IWS policy/protocol for patients on opioids/sedatives ≥ 72 hours
Number of subjects: 1506
Study 37283627 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (200 μg/kg, single oral dose)
Number of subjects: 248
Study 37283627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 37283819 — intervention group
Group type: EXPERIMENTAL
Intervention: rFIXFc prophylaxis
Number of subjects: 92
Study 37283943 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-SARS-CoV-2 antibodies tested at baseline, 8 weeks, and 16 weeks.
Number of subjects: 648
Study 37283943 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG titer measurement over time.
Number of subjects: 648
Study 37283969 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mL (135 μg) candidate vaccine
Number of subjects: 24
Study 37283969 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mL (270 μg) candidate vaccine
Number of subjects: 24
Study 37283969 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate vaccine (both dosages)
Number of subjects: 24
Study 37283969 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 24
Study 37283972 — intervention group
Group type: EXPERIMENTAL
Intervention: sIPV
Number of subjects: 381
Study 37283977 — intervention group
Group type: EXPERIMENTAL
Intervention: LLDT-8 0.5 mg daily
Number of subjects: 149
Study 37283977 — intervention group
Group type: EXPERIMENTAL
Intervention: LLDT-8 1 mg daily
Number of subjects: 149
Study 37283977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 37283994 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriosis symptoms (pelvic pain, dyspareunia, heavy bleeding)
Number of subjects: 40
Study 37283994 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriosis impacts
Number of subjects: 40
Study 37284020 — intervention group
Group type: EXPERIMENTAL
Intervention: Social alarms
Number of subjects: 278
Study 37284066 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37284181 — intervention group
Group type: EXPERIMENTAL
Intervention: Auriculotherapy (3 sessions, 1 month apart, using semi-permanent needles)
Number of subjects: 90
Study 37284181 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 90
Study 37284297 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal avoidance prophylactic cranial irradiation (HA-PCI)
Number of subjects: 161
Study 37284297 — intervention group
Group type: COMPARATOR
Intervention: Standard prophylactic cranial irradiation (PCI)
Number of subjects: 161
Study 37284327 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 10
Study 37284327 — intervention group
Group type: COMPARATOR
Intervention: Sham spinal procedure
Number of subjects: 10
Study 37284613 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroid autografts
Number of subjects: 115
Study 37284759 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvenous phrenic nerve stimulation (TPNS) on
Number of subjects: 48
Study 37284759 — intervention group
Group type: COMPARATOR
Intervention: Transvenous phrenic nerve stimulation (TPNS) off
Number of subjects: 48
Study 37284847 — intervention group
Group type: EXPERIMENTAL
Intervention: NK-1 receptor antagonist (fosaprepitant 150 mg IV or aprepitant 130 mg IV)
Number of subjects: 690
Study 37284847 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no NK-1 receptor antagonist)
Number of subjects: 690
Study 37285038 — intervention group
Group type: EXPERIMENTAL
Intervention: High-precision image-guided cardiac SBRT with 25 Gy delivered to the VT substrate.
Number of subjects: 5
Study 37285046 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pressure bandage (45-55 mmHg)
Number of subjects: 21
Study 37285046 — intervention group
Group type: COMPARATOR
Intervention: Low-pressure bandage (20-30 mmHg)
Number of subjects: 21
Study 37285069 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 105
Study 37285069 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 105
Study 37285075 — intervention group
Group type: EXPERIMENTAL
Intervention: First magnesium tertile
Number of subjects: 253
Study 37285075 — intervention group
Group type: EXPERIMENTAL
Intervention: Third magnesium tertile
Number of subjects: 253
Study 37285075 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D sufficient participants in first magnesium tertile
Number of subjects: 253
Study 37285075 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved magnesium tertiles at week 4
Number of subjects: 253
Study 37285075 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue scores
Number of subjects: 253
Study 37285081 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 2.5-10.0 mg
Number of subjects: 24
Study 37285081 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 2.5-15.0 mg
Number of subjects: 24
Study 37285081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 37285113 — intervention group
Group type: EXPERIMENTAL
Intervention: MOTS-c peptide treatment
Number of subjects: 100
Study 37285113 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 100
Study 37285133 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided i-CBT
Number of subjects: 1319
Study 37285133 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided i-CBT
Number of subjects: 1319
Study 37285133 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 1319
Study 37285195 — intervention group
Group type: EXPERIMENTAL
Intervention: CSM-IBD intervention (8-session program delivered over 8-12 weeks with check-ins with a registered nurse)
Number of subjects: 54
Study 37285195 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 54
Study 37285278 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg once daily (o.d.)
Number of subjects: 0
Study 37285278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37285326 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus coryniformis K8 (3×10^9 CFU) per day
Number of subjects: 255
Study 37285326 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 255
Study 37285482 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal pertussis vaccination
Number of subjects: 0
Study 37285526 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart transplantation from circulatory-death donor
Number of subjects: 180
Study 37285526 — intervention group
Group type: COMPARATOR
Intervention: Heart transplantation from brain-death donor
Number of subjects: 180
Study 37285718 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin monotherapy
Number of subjects: 80
Study 37285718 — intervention group
Group type: COMPARATOR
Intervention: Eribulin plus anlotinib
Number of subjects: 80
Study 37285766 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval-based inspiratory muscle training (H-IMT)
Number of subjects: 34
Study 37285766 — intervention group
Group type: COMPARATOR
Intervention: Control group (unloaded IMT)
Number of subjects: 34
Study 37285801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol OTF strips (40,000 IU) administered for 12 weeks
Number of subjects: 20
Study 37285865 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib plus enzalutamide (talazoparib 0.5 mg + enzalutamide 160 mg)
Number of subjects: 805
Study 37285865 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus enzalutamide (placebo + enzalutamide 160 mg)
Number of subjects: 805
Study 37285865 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib plus enzalutamide
Number of subjects: 805
Study 37285925 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotilaner ophthalmic solution 0.25%
Number of subjects: 412
Study 37285925 — intervention group
Group type: COMPARATOR
Intervention: Vehicle without lotilaner
Number of subjects: 412
Study 37286048 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 intravenous dose of 24 mg dexamethasone (DX1)
Number of subjects: 252
Study 37286048 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 intravenous doses of 24 mg dexamethasone (DX2)
Number of subjects: 252
Study 37286048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 37286048 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary outcome: average peak pain intensity during the 40FPW, TUG, 30CST and SCT.
Number of subjects: 252
Study 37286131 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support training for family caregivers
Number of subjects: 0
Study 37286131 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37286215 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR vaccine (M-M-R VaxPro)
Number of subjects: 6540
Study 37286215 — intervention group
Group type: COMPARATOR
Intervention: Placebo (solvent only)
Number of subjects: 6540
Study 37286215 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR vaccine
Number of subjects: 6540
Study 37286268 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 170
Study 37286268 — intervention group
Group type: COMPARATOR
Intervention: bDMARDs
Number of subjects: 170
Study 37286268 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib and bDMARDs
Number of subjects: 170
Study 37286303 — intervention group
Group type: EXPERIMENTAL
Intervention: Tebentafusp plus durvalumab
Number of subjects: 85
Study 37286303 — intervention group
Group type: EXPERIMENTAL
Intervention: Tebentafusp plus tremelimumab
Number of subjects: 85
Study 37286303 — intervention group
Group type: EXPERIMENTAL
Intervention: Tebentafusp plus durvalumab and tremelimumab
Number of subjects: 85
Study 37286303 — intervention group
Group type: EXPERIMENTAL
Intervention: Tebentafusp (alone or in combination)
Number of subjects: 85
Study 37286303 — intervention group
Group type: EXPERIMENTAL
Intervention: Tebentafusp with checkpoint inhibitors
Number of subjects: 85
Study 37286305 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 65
Study 37286312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical recombinant BCG (rBCG: VPM1002BC) applied weekly for three instillations followed by four cycles of neoadjuvant cisplatin/gemcitabine every 3 weeks.
Number of subjects: 0
Study 37286312 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg every 3 weeks started together with rBCG and given for four cycles, continued as maintenance therapy after surgery every 3 weeks for 13 cycles.
Number of subjects: 0
Study 37286317 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency single-level cerclage with vaginal progesterone
Number of subjects: 78
Study 37286317 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency double-level cerclage with vaginal progesterone
Number of subjects: 78
Study 37286319 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual and auditory contact via a head-mounted display (HMD) showing a live video of the newborn, used by the mother during surgery.
Number of subjects: 70
Study 37286319 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (standard care) for mothers after CS.
Number of subjects: 70
Study 37286319 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual and auditory contact via HMD.
Number of subjects: 70
Study 37286319 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (standard care).
Number of subjects: 70
Study 37286324 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX treatment with circadian-based telemonitoring-telecare platform
Number of subjects: 67
Study 37286324 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX treatment
Number of subjects: 67
Study 37286457 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioligand treatment
Number of subjects: 0
Study 37286557 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) 6.4 mg/kg every 3 weeks in cohort A (HER2-positive, IHC 3+ or IHC 2+/ISH+).
Number of subjects: 86
Study 37286557 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab deruxtecan (T-DXd) in cohorts B and C (IHC 2+/ISH- and IHC 1+ respectively).
Number of subjects: 86
Study 37286557 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) in cohort A.
Number of subjects: 86
Study 37286774 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical student-guided smoking cessation program
Number of subjects: 688
Study 37286774 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 688
Study 37286774 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical student knowledge assessment
Number of subjects: 688
Study 37286846 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (32-34 °C for 24 h) plus standard care
Number of subjects: 270
Study 37286846 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 270
Study 37286927 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant
Number of subjects: 930
Study 37286927 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 930
Study 37287026 — intervention group
Group type: EXPERIMENTAL
Intervention: PSH Overdose Prevention (POP) Toolkit training, time-limited practice facilitation, and learning collaboratives delivered to staff and tenant implementation champions over a 6-month period.
Number of subjects: 20
Study 37287026 — intervention group
Group type: EXPERIMENTAL
Intervention: PSH staff and tenant survey questionnaires and analysis of tenant Medicaid data.
Number of subjects: 20
Study 37287026 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with key stakeholders.
Number of subjects: 20
Study 37287037 — intervention group
Group type: EXPERIMENTAL
Intervention: TLR4 and related genes (including SNP rs4986790 and rs5030719)
Number of subjects: 349
Study 37287080 — intervention group
Group type: EXPERIMENTAL
Intervention: Current glucocorticoid (GC) treatment
Number of subjects: 483
Study 37287080 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative GC dose and duration of use
Number of subjects: 483
Study 37287080 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group: patients not currently taking GCs)
Number of subjects: 483
Study 37287104 — intervention group
Group type: EXPERIMENTAL
Intervention: Former WHO definition (PTA > 25 dB)
Number of subjects: 1634
Study 37287104 — intervention group
Group type: EXPERIMENTAL
Intervention: New WHO definition (PTA ≥ 20 dB)
Number of subjects: 1634
Study 37287317 — intervention group
Group type: EXPERIMENTAL
Intervention: DDI (Decision to Delivery Interval) of more than 20 minutes
Number of subjects: 228
Study 37287317 — intervention group
Group type: COMPARATOR
Intervention: DDI of 20 minutes or less
Number of subjects: 228
Study 37287317 — intervention group
Group type: EXPERIMENTAL
Intervention: DDI longer than 20 minutes
Number of subjects: 228
Study 37287321 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS over the left inferior frontal gyrus (IFG)
Number of subjects: 0
Study 37287321 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study 37287321 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS over the left IFG
Number of subjects: 0
Study 37287520 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Diabetes Prevention Program (DPP)
Number of subjects: 14
Study 37287870 — intervention group
Group type: EXPERIMENTAL
Intervention: nal-IRI/5-FU/folinic acid
Number of subjects: 58
Study 37287870 — intervention group
Group type: COMPARATOR
Intervention: docetaxel
Number of subjects: 58
Study 37287922 — intervention group
Group type: EXPERIMENTAL
Intervention: hsa-miR-5096
Number of subjects: 24
Study 37287922 — intervention group
Group type: EXPERIMENTAL
Intervention: hsa-let-7i-3p
Number of subjects: 24
Study 37287922 — intervention group
Group type: EXPERIMENTAL
Intervention: hsa-miR-4311
Number of subjects: 24
Study 37287970 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg methylprednisolone intravenously for 3 consecutive days followed by tocilizumab (TCZ) monotherapy
Number of subjects: 16
Study 37288292 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral neck exploration, left thyroid lobectomy, and transcervical thymectomy.
Number of subjects: 1
Study 37288292 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat preoperative imaging identified a 7-mm × 5-mm adenoma on 4DCT.
Number of subjects: 1
Study 37288326 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour infusion group
Number of subjects: 96
Study 37288326 — intervention group
Group type: COMPARATOR
Intervention: 2-hour infusion group
Number of subjects: 96
Study 37288553 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter or surgical ablation of long-standing persistent atrial fibrillation
Number of subjects: 83
Study 37288553 — intervention group
Group type: EXPERIMENTAL
Intervention: LA contractile strain at 3 months post-ablation
Number of subjects: 83
Study 37288562 — intervention group
Group type: EXPERIMENTAL
Intervention: metagenomic next-generation sequencing (mNGS)
Number of subjects: 0
Study 37288570 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 SPC class combinations
Number of subjects: 3833
Study 37288570 — intervention group
Group type: EXPERIMENTAL
Intervention: All medication class regimens
Number of subjects: 3833
Study 37288570 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 or more medication classes
Number of subjects: 3833
Study 37288582 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant immunochemotherapy (NAICT) with toripalimab (PD-1 inhibitor) and albumin paclitaxel/cisplatin (TTP)
Number of subjects: 20
Study 37288701 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 6104
Study 37288954 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir plus 2 NRTIs
Number of subjects: 30
Study 37289256 — intervention group
Group type: EXPERIMENTAL
Intervention: Geptanolimab (GB226) 3 mg/kg intravenously every 2 weeks until disease progression or intolerable toxicity
Number of subjects: 25
Study 37289256 — intervention group
Group type: EXPERIMENTAL
Intervention: Geptanolimab (GB226)
Number of subjects: 25
Study 37289263 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankaferd hemostat
Number of subjects: 66
Study 37289263 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate
Number of subjects: 66
Study 37289335 — intervention group
Group type: EXPERIMENTAL
Intervention: High hemoglobin target (11-13 g/dl) with darbepoetin alfa
Number of subjects: 479
Study 37289335 — intervention group
Group type: COMPARATOR
Intervention: Low hemoglobin target (9-11 g/dl)
Number of subjects: 479
Study 37289448 — intervention group
Group type: EXPERIMENTAL
Intervention: SB15 (2 mg every 4 weeks for the first 12 weeks, then every 8 weeks up to week 48)
Number of subjects: 449
Study 37289448 — intervention group
Group type: COMPARATOR
Intervention: AFL (2 mg every 4 weeks for the first 12 weeks, then every 8 weeks up to week 48)
Number of subjects: 449
Study 37289448 — intervention group
Group type: EXPERIMENTAL
Intervention: SB15
Number of subjects: 449
Study 37289448 — intervention group
Group type: COMPARATOR
Intervention: AFL
Number of subjects: 449
Study 37289451 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative Stereotactic Radiosurgery (SRS) at a median dose of 15 Gy in 1 fraction or 24 Gy in 3 fractions, delivered at a median of 2 days before resection.
Number of subjects: 404
Study 37289451 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative Stereotactic Radiosurgery (SRS)
Number of subjects: 404
Study 37289454 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer comparison feedback (monthly emails)
Number of subjects: 201
Study 37289454 — intervention group
Group type: COMPARATOR
Intervention: Control group (no peer comparison feedback)
Number of subjects: 201
Study 37289502 — intervention group
Group type: EXPERIMENTAL
Intervention: State cannabis registration (SCR) card ownership
Number of subjects: 0
Study 37289502 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37289535 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (MM)
Number of subjects: 328
Study 37289535 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis (HYP)
Number of subjects: 328
Study 37289535 — intervention group
Group type: COMPARATOR
Intervention: Active education control (ED)
Number of subjects: 328
Study 37289541 — intervention group
Group type: EXPERIMENTAL
Intervention: Flu-IVIG treatment in IBV-infected patients (n = 62)
Number of subjects: 112
Study 37289541 — intervention group
Group type: EXPERIMENTAL
Intervention: Flu-IVIG treatment in IAV-infected patients (n = 50)
Number of subjects: 112